# Filing Detail

Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001213900-21-008444
Filing Date
2021-02-11
Accepted
2021-02-11 16:00:40
Documents
10

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PROSPECTUS | ea135201-424b3_aditxtherap.htm | 424B3 | 1552338
2 | GRAPHIC | image_001.jpg | GRAPHIC | 7724
3 | GRAPHIC | image_002.jpg | GRAPHIC | 52738
4 | GRAPHIC | image_003.jpg | GRAPHIC | 67669
5 | GRAPHIC | image_004.jpg | GRAPHIC | 56783
6 | GRAPHIC | image_005.jpg | GRAPHIC | 40287
7 | GRAPHIC | image_006.jpg | GRAPHIC | 33092
8 | GRAPHIC | image_007.jpg | GRAPHIC | 32657
9 | GRAPHIC | image_008.jpg | GRAPHIC | 81259
10 | GRAPHIC | image_009.jpg | GRAPHIC | 8502
| Complete submission text file | 0001213900-21-008444.txt |  | 2078991

Mailing Address 2569 WYANDOTTE, ST. SUITE 101 MOUNTAIN CA 94043
Business Address 2569 WYANDOTTE, ST. SUITE 101 MOUNTAIN CA 94043 909-488-0844
Aditx Therapeutics, Inc. (Filer) CIK: 0001726711 (see all company filings)

EIN.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-252711 | Film No.: 21619477
SIC: 2834 Pharmaceutical Preparations